Recent Posts
- ImmunityBio Announces Presentation at ASCO GI 2023 of Fully Enrolled Trial in Third-Line and Greater Pancreatic Cancer and Update on FDA Type B Meetings Regarding Paths to Registration
- ASCO Genitourinary Cancers Symposium 2023
- ASCO Gastrointestinal Cancers Symposium 2023
- ImmunityBio Announces $157 Million Financing From Nant and Institutional Investor
- ImmunityBio to Participate in 34th Annual Piper Sandler Healthcare Conference